{"nctId":"NCT00577993","briefTitle":"Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients","startDateStruct":{"date":"1998-03-16","type":"ACTUAL"},"conditions":["Lymphoma"],"count":210,"armGroups":[{"label":"1: FND + Rituximab Followed by Interferon","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fludarabine","Drug: Novantrone","Drug: Decadron","Drug: Rituximab","Drug: Interferon"]},{"label":"2: FND Followed by Interferon & Rituximab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fludarabine","Drug: Novantrone","Drug: Decadron","Drug: Rituximab","Drug: Interferon"]},{"label":"3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Novantrone","Drug: Decadron","Drug: Rituximab","Drug: Interferon","Drug: Doxorubicin","Drug: Vincristine","Drug: Bleomycin","Drug: Cyclophosphamide","Drug: Etoposide","Drug: Cisplatin","Drug: Ara-C","Drug: Methyl-Prednisolone","Drug: Procarbazine","Drug: Prednisone"]}],"interventions":[{"name":"Fludarabine","otherNames":["2-fluoro-Ara Amp"]},{"name":"Novantrone","otherNames":["Mitoxantrone"]},{"name":"Decadron","otherNames":["Dexamethasone"]},{"name":"Rituximab","otherNames":["Chimeric Anti-CD20 Antibody","Anti-CD20","IDEC-C2B8"]},{"name":"Interferon","otherNames":["Interferon Alpha-2b","IFN"]},{"name":"Doxorubicin","otherNames":[]},{"name":"Vincristine","otherNames":[]},{"name":"Bleomycin","otherNames":[]},{"name":"Cyclophosphamide","otherNames":[]},{"name":"Etoposide","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Ara-C","otherNames":[]},{"name":"Methyl-Prednisolone","otherNames":[]},{"name":"Procarbazine","otherNames":[]},{"name":"Prednisone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Previously untreated stage IV indolent B-cell lymphoma \\[Amendment May 2001: eligibility restricted to follicular lymphoma\\]\n2. Age \\<76\n\nExclusion Criteria:\n\nN/A","healthyVolunteers":false,"sex":"ALL","maximumAge":"76 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Overall Survival (10 Years) by Treatment","description":"Overall Survival is the time from date of treatment start until date of death due to any cause or last Follow-up within 10 years.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Progression Free Survival (10 Years) by Treatment","description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":67,"n":78},"commonTop":["Fatigue","Neutropenia","Alopecia","Abdominal Pain","Infection"]}}}